Design, Synthesis, and Biological Evaluation of 3,4-Diarylmaleimides as Angiogenesis Inhibitors
作者:Christian Peifer、Thomas Stoiber、Eberhard Unger、Frank Totzke、Christoph Schächtele、Dieter Marmé、Ruth Brenk、Gerhard Klebe、Dieter Schollmeyer、Gerd Dannhardt
DOI:10.1021/jm0580297
日期:2006.2.1
The new analogue 2 of combretastatin A-4 was discovered to be an inhibitor of tubulin polymerization with an IC50 of 7.6 microM and reduced angiogenesis in the in vivo chick embryo model. Interestingly, in a series of 2,3-diarylmaleimides closely related to this lead, no other compound was found to be active in the tubulin polymerization assay. However, by screening in the in vivo chick embryo assay
发现康美他汀A-4的新类似物2是微管蛋白聚合的抑制剂,在体内鸡胚模型中的IC50为7.6 microM,并减少了血管生成。有趣的是,在一系列与该铅紧密相关的2,3-二芳基马来酰亚胺中,在微管蛋白聚合测定中未发现其他化合物具有活性。然而,通过在体内进行筛选,将雏鸡胚胎测定法10鉴定为有效的血管生成抑制剂,表明了另一种靶标。确实,分子建模研究表明在模型激酶CDK2的ATP结合位点有一个合理的10结合模式。根据这些结果,在10种类似的12种蛋白激酶中筛选了10种类似物的抑制活性,发现10种对VEGF-R2的高亲和力表明IC50为2.5 nM。